Shaohua Li1,2, Jie Mei1,2, Qiaoxuan Wang2,3, Feng Shi4, Hongyan Liu5, Ming Zhao2,6, Lianghe Lu1,2, Yihong Ling2,7, Zhixing Guo2,8, Yabing Guo5, Xiaoming Chen4, Ming Shi1,2, Wan Yee Lau9, Wei Wei1,2, Rongping Guo1,2. 1. Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 3. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 4. Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 5. State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. 6. Department of Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China. 7. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. 8. Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, China. 9. Faculty of Medicine, the Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.
Abstract
BACKGROUND: To compare the treatment effectiveness and safety among transarterial infusion chemotherapy (TAI) with FOLFOX regimen, transarterial chemoembolization (TACE), and sorafenib in patients with BCLC stage C hepatocellular carcinoma (HCC). METHODS: The data of consecutive patients with BCLC stage C HCC treated with TAI, TACE, or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed. Propensity-score matched (PSM) analysis was pairwise performed to reduce selection bias. Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method, log-rank test, Cox regression models, and χ2 test. RESULTS: The median overall survival (OS) in the matched TAI cohort was significantly longer than the sorafenib cohort (19.6 vs. 7.5 months, P=0.009), and the TACE cohort (estimated 27.8 vs. 6.6 months, P<0.001). The difference in median progression-free survival (PFS) between the matched TAI and sorafenib cohorts was not significant (5.8 vs. 2.3 months, P=0.219). The median PFS in the matched TAI cohort was significantly longer than the TACE cohort (6.5 vs. 2.8 months, P<0.001). The objective response rate (ORR) in the matched TAI cohort was significantly higher than the sorafenib cohort (36.4% vs. 0.0%, P<0.001) and the TACE cohort (48.7% vs. 4.7%, P<0.001). The incidences of adverse events (AEs) were similar among these three cohorts. CONCLUSIONS: TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
BACKGROUND: To compare the treatment effectiveness and safety among transarterial infusion chemotherapy (TAI) with FOLFOX regimen, transarterial chemoembolization (TACE), and sorafenib in patients with BCLC stage C hepatocellular carcinoma (HCC). METHODS: The data of consecutive patients with BCLC stage C HCC treated with TAI, TACE, or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed. Propensity-score matched (PSM) analysis was pairwise performed to reduce selection bias. Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method, log-rank test, Cox regression models, and χ2 test. RESULTS: The median overall survival (OS) in the matched TAI cohort was significantly longer than the sorafenib cohort (19.6 vs. 7.5 months, P=0.009), and the TACE cohort (estimated 27.8 vs. 6.6 months, P<0.001). The difference in median progression-free survival (PFS) between the matched TAI and sorafenib cohorts was not significant (5.8 vs. 2.3 months, P=0.219). The median PFS in the matched TAI cohort was significantly longer than the TACE cohort (6.5 vs. 2.8 months, P<0.001). The objective response rate (ORR) in the matched TAI cohort was significantly higher than the sorafenib cohort (36.4% vs. 0.0%, P<0.001) and the TACE cohort (48.7% vs. 4.7%, P<0.001). The incidences of adverse events (AEs) were similar among these three cohorts. CONCLUSIONS: TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
Authors: Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann Journal: Nat Med Date: 2017-02-27 Impact factor: 53.440
Authors: Bas Groot Koerkamp; Eran Sadot; Nancy E Kemeny; Mithat Gönen; Julie N Leal; Peter J Allen; Andrea Cercek; Ronald P DeMatteo; T Peter Kingham; William R Jarnagin; Michael I D'Angelica Journal: J Clin Oncol Date: 2017-04-20 Impact factor: 44.544
Authors: A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer Journal: Oncogene Date: 2009-11-02 Impact factor: 9.867
Authors: Hyun Young Woo; Si Hyun Bae; Jun Yong Park; Kwang Hyub Han; Ho Jong Chun; Byung Gil Choi; Hyeon U Im; Jong Young Choi; Seung Kew Yoon; Jae Youn Cheong; Sung Won Cho; Byoung Kuk Jang; Jae Seok Hwang; Sang Gyune Kim; Young Seok Kim; Yeon Seok Seo; Hyung Joon Yim; Soon Ho Um Journal: Cancer Chemother Pharmacol Date: 2009-09-18 Impact factor: 3.333
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079